Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · melanoma-umap@29

SAMN03290894

—

7427bedc-14eb-50b6-8f7f-db64b20c4f2c

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • ALLOGRAFT_REJECTION+0.400
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.400
  • IL6_JAK_STAT3_SIGNALING+0.400
  • INFLAMMATORY_RESPONSE+0.400
  • ANGIOGENESIS+0.300
  • APICAL_JUNCTION+0.300
  • APICAL_SURFACE+0.300
  • E2F_TARGETS+0.300
  • G2M_CHECKPOINT+0.300
  • INTERFERON_GAMMA_RESPONSE+0.300

Top 10 suppressed

  • OXIDATIVE_PHOSPHORYLATION-0.600
  • MYC_TARGETS_V2-0.500
  • REACTIVE_OXYGEN_SPECIES_PATHWAY-0.400
  • DNA_REPAIR-0.300
  • FATTY_ACID_METABOLISM-0.300
  • HEME_METABOLISM-0.300
  • ADIPOGENESIS-0.200
  • CHOLESTEROL_HOMEOSTASIS-0.100
  • GLYCOLYSIS-0.100
  • MTORC1_SIGNALING-0.100

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

7 twins match this tumor's tissue · 3 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SAMN03290911
melanoma-umap@29
——0.850
2s_150203_5b
medullo-epn-umap@date-based
EPNPosterior Fossa EPN0.843
333d6df2f-acc4-4c91-b924-4fb2f519e8ed
melanoma-umap@29
——0.829
4TCGA-56-8625-01A-11R-2403-07
lung-landscapes@6
—cohortSQ10.817
5MDT-AP-2796
medullo-epn-umap@date-based
MedMedulloblastoma0.814
6MDT-AP-2304
medullo-epn-umap@date-based
MedMedulloblastoma0.812
7aad90266-d469-4986-b260-d0df4c2f48e7
colon-landscapes@1
——0.805
8TCGA-56-8503-01A-11R-2403-07
lung-landscapes@6
—cohortSQ10.802
9c56e13bb-f1b0-4ee3-85c1-807c7c3bcef9
colon-landscapes@1
——0.801
10TCGA-C8-A8HQ-01A-11R-A36F-07
breast-umap@18
—C0.800

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 30 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
ALLOGRAFT_REJECTION0.400Idelalisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.400Inavolisib— uncovered
IL6_JAK_STAT3_SIGNALING0.400Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.400Idelalisib— uncovered
ANGIOGENESIS0.300Remibrutinib— uncovered
APICAL_JUNCTION0.300Inavolisib— uncovered
APICAL_SURFACE0.300Temsirolimus— uncovered
E2F_TARGETS0.300Inavolisib— uncovered
G2M_CHECKPOINT0.300Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.300Idelalisib— uncovered
KRAS_SIGNALING_UP0.300Inavolisib— uncovered
TGF_BETA_SIGNALING0.300Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.300Inavolisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.300Inavolisib— uncovered
APOPTOSIS0.200Idelalisib— uncovered
COAGULATION0.200Binimetinib— uncovered
COMPLEMENT0.200Inavolisib— uncovered
ESTROGEN_RESPONSE_LATE0.200Idelalisib— uncovered
IL2_STAT5_SIGNALING0.200Idelalisib— uncovered
PANCREAS_BETA_CELLS0.200Cobimetinib— uncovered